...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New shares issued?

tada,,,thats great for those who wish to stay the course forever and a day,,,it certainly does not alleviate the existing shareholders who would like to exit the play. The retail investors here have a chunk of change tied up, including me. What is the benefit of keeping the company private anyway??...if 208 hits and epigenics become real science to the world where does that leave ZCC??,,we have at this time, and as far as we know into the future, no way to determine the worth of this company!!,,We can make guesstimates but that means absolutley nothing until the open market speaks!! And as far as DM being too busy then I answer that point with the fact that there are ample CEOs out there very willing and very capable of steering the ship!!,,maybe even better than DM!!,,,nope,,its all just a cop out by DMs team,,no reason not to have this company trading in open market where it has to at some point to be of any value to its existing shareholders!!,,again it is as though we own part of a rare coin,,,,which we think is worth something,,, but bidders are not allowed to make offers,,,,,,,,,,,Thats the reality and an opinion.

Share
New Message
Please login to post a reply